Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXW1Y3)

Drug Name

SKF-96067 Drug Info

Synonyms

115607-61-9; Skf-96067; F-96067; SKF96067; 3-Butyryl-4-(2-methylphenylamino)-8-methoxyquinoline; CHEMBL327717; SK-96067; 1-Butanone,1-[8-methoxy-4-[(2-methylphenyl)amino]-3-quinolinyl]-; 1-Butanone, 1-[8-methoxy-4-[(2-methylphenyl)amino]-3-quinolinyl]-; 1-Butanone, 1-(8-methoxy-4-((2-methylphenyl)amino)-3-quinolinyl)-; MAVJDLHBPIXVJL-UHFFFAOYSA-N; AC1MIWAF; ACMC-1BTM4; SCHEMBL451221; ZINC3665; CTK4A9399; DTXSID40151146; BDBM50001254; HY-U00042; 1-[8-METHOXY-4-[(2-METHYLPHENYL)AMINO]-3-QUINOLINYL]-1-BUTANONE

Indication

Disease Entry	ICD 11	Status	REF
Peptic ulcer	DA61	Discontinued in Phase 3	[1]

Cross-matching ID

PubChem CID: 3081087
CAS Number: CAS 115607-61-9
TTD Drug ID: DMXW1Y3

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Gastric H(+)/K(+) ATPase (Proton pump)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[3]
Pantoprazole	DMSVOCZ	Gastrinoma	2C10.1	Approved	[3]
Dexlansoprazole	DM1DBV5	Erosive esophagitis	DA25.0	Approved	[3]
Esomeprazole	DM7BN0X	Cystic fibrosis	CA25	Approved	[3]
Vonoprazan	DMO6315	Helicobacter infection	DA42-DA63	Approved	[4]
RQ-00000004	DM9T8OF	Gastroesophageal reflux disease	DA22.Z	Phase 3	[5]
YH-4808	DMCHFB0	Duodenal ulcer	DA63	Phase 2	[6]
S-tenatoprazole	DMJ1DIB	Peptic ulcer	DA61	Phase 2	[7]
AZD-0865	DMM0N1F	Gastrointestinal disease	DE2Z	Phase 2	[8]
LEMINOPRAZOLE	DMBKNJT	Ulcerative colitis	DD71	Discontinued in Preregistration	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gastric H(+)/K(+) ATPase (Proton pump)	TTLOKXP	ATP4A_HUMAN; ATP4B_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001218)
2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2008
5	N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. J Pharmacol Exp Ther. 2009 Feb;328(2):671-9.
6	Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil.2012 Aug;24(8):697-704.
7	Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in heal... Aliment Pharmacol Ther. 2004 Mar 15;19(6):655-62.
8	Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase. Biochem Pharmacol. 2007 Jan 15;73(2):198-205.
9	Vasoinhibitory effect of leminoprazole, a H+,K(+)-ATPase inhibitor, on rat aortic rings. Gen Pharmacol. 1996 Jan;27(1):117-21.